Spots Global Cancer Trial Database for Immune Response for Patients With Metastatic Breast Cancer Treated by Everolimus
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Immune Response for Patients With Metastatic Breast Cancer Treated by Everolimus
Official Title: Study of the Immune Response T Anti-tumoral Cluster of Differentiation 4 (CD4) for Patients Treated for a Metastatic Breast Cancer by Everolimus Within the Framework of Its Marketing Authorization
Study ID: NCT02854618
Conditions
Interventions
Study Description
Brief Summary: This study evaluates the immune response for patients affected by metastatic breast cancer treated by everolimus
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
Locations
Centre Hospitalier Régional Universitaire, Besançon, , France
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
